Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

11 terminated/withdrawn out of 33 trials

Success Rate

52.2%

-34.3% vs industry average

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

83%

10 of 12 completed trials have results

Key Signals

1 recruiting10 with results8 terminated

Enrollment Performance

Analytics

Phase 1
21(70.0%)
Phase 2
7(23.3%)
Early Phase 1
1(3.3%)
Phase 3
1(3.3%)
30Total
Phase 1(21)
Phase 2(7)
Early Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (33)

Showing 20 of 33 trials
NCT04224493Phase 3Active Not Recruiting

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Role: lead

NCT05983965Phase 1Terminated

Study of Tazemetostat in Lymphoid Malignancies

Role: collaborator

NCT04241835Phase 1Terminated

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Role: lead

NCT05407441Phase 1Active Not Recruiting

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Role: collaborator

NCT05994235Phase 2Active Not Recruiting

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

Role: collaborator

NCT05618366Phase 1Terminated

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Role: collaborator

NCT04179864Phase 1Terminated

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Role: lead

NCT04705818Phase 2Completed

Combining Epigenetic And Immune Therapy to Beat Cancer.

Role: collaborator

NCT05551936Phase 1Active Not Recruiting

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Role: collaborator

NCT04917042Phase 2Active Not Recruiting

Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

Role: collaborator

NCT06068881Phase 2Withdrawn

A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation

Role: lead

NCT04204941Phase 1Terminated

Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

Role: lead

NCT02875548Phase 1Completed

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

Role: lead

NCT05934838Phase 1Recruiting

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Role: collaborator

NCT02601950Phase 2Completed

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Role: lead

NCT05121103Phase 1Terminated

A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

Role: lead

NCT04846478Phase 1Active Not Recruiting

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Role: collaborator

NCT04537715Phase 1Completed

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

Role: lead

NCT02889523Phase 1Active Not Recruiting

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

Role: collaborator

NCT02601937Phase 1Completed

EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Role: lead